Skip to main content
Premium Trial:

Request an Annual Quote

Biotage to Buy Argonaut s Flash Chromatography Business for $21.1M Next Month

NEW YORK, April 8 (GenomeWeb News) - Biotage is close to closing a deal to purchase stock and certain assets of Argonaut Technologies' flash chromatography business for $21.2 million in cash.

 

The closing of the deal is expected to happen "directly after" a shareholder's meeting in the second half of May, if Biotage shareholders vote in favor of the acquisition, Biotage CEO Jeff Bork said today.

 

In February, Biotage entered into an agreement to purchase Argonauts' assets for $19.9 million in cash. Under the amended agreement, Argonaut is selling additional assets, including specified liabilities, warranty service and maintenance, and accounts payable of up to $350,000 associated with Argonauts' remaining Process Development Products and Services business.

 

Following the close of the deal, Argonaut intends to distribute to stockholders a significant portion of the net proceeds.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.